Arbutus Biopharma Confirms Nasdaq Listing for ABUS Common Shares

TL;DR

**ABUS confirms Nasdaq listing, business as usual.**

AI Summary

Arbutus Biopharma Corporation filed an 8-K on January 8, 2024, to report on its current status, including its registration of Common Shares, without par value, under the trading symbol ABUS on The Nasdaq Stock Market LLC. This filing primarily serves to update administrative and registration details, confirming the company's continued listing and compliance. For investors, this matters because it reaffirms Arbutus's presence on a major exchange, ensuring liquidity and transparency for its stock, ABUS.

Why It Matters

This filing confirms Arbutus Biopharma's continued compliance and listing on The Nasdaq Stock Market LLC, which is crucial for maintaining investor confidence and stock liquidity.

Risk Assessment

Risk Level: low — This 8-K is an administrative filing confirming existing information, posing minimal new risk to investors.

Analyst Insight

A smart investor would note this administrative filing confirms ongoing compliance and listing, but it doesn't contain new financial or operational news to directly impact investment decisions. It's a routine check-in.

Key Players & Entities

• Arbutus Biopharma Corporation (company) — the registrant filing the 8-K
• ABUS (company) — trading symbol for Arbutus Biopharma's Common Shares
• The Nasdaq Stock Market LLC (company) — exchange where Arbutus Biopharma's Common Shares are registered
• January 8, 2024 (date) — date of earliest event reported and filing date

FAQ

From the Filing

0001171843-24-000113.txt : 20240108 0001171843-24-000113.hdr.sgml : 20240108 20240108073116 ACCESSION NUMBER: 0001171843-24-000113 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 24518344 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 f8k_010624.htm FORM 8-K Form 8-K 0001447028 False 0001447028 2024-01-08 2024-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  January 8, 2024 _______________________________ Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) _______________________________ British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 701 Veterans Circle Warminster , Pennsylvania 18974 (Address of Principal Executive Offices) (Zip Code) ( 267 ) 469-0914 (Registrant's telephone number, including area code)   (Former name or former address, if changed since last report) _______________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, without par value ABUS The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 2.02. Results of Operations and Financial Condition. On January 8, 2024, Arbutus Biopharma Corporation (the "Company") issued a press release (the "Press Release") announcing its 2024 corporate objectives and provided certain estimated and projected financial information, including its estimated cash, cash equivalents and investments as of December 31, 2023. The amounts included in the Press Release are preliminary, have not been audited and are subject t